New hope for rectal cancer: extra chemo may save the rectum
NCT ID NCT02514278
First seen May 15, 2026 · Last updated Jun 20, 2026 · Updated 6 times
Summary
This phase 3 trial tested whether adding two months of Folfirinox chemotherapy before standard radiation and chemo could help more patients with early-stage rectal cancer avoid major surgery. 218 adults with small, low-lying tumors were enrolled. The goal was to see if more patients could keep their rectum and have no stoma one year after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Département de chirurgie digestive, Institut Gustave Roussy
Villejuif, France
-
GH Paris Saint Joseph
Paris, France
-
Service d'Oncologie et Radiothérapie, Centre Azuréen de Cancérologie
Mougins, France
-
Service de Chirurgie Digestive et Oncologique, Hôpital Bicêtre - APHP
Paris, France
-
Service de Chirurgie Digestive, CHU Amiens Picardie
Amiens, France
-
Service de Chirurgie Digestive, CHU Carémeau - Nîmes
Nîmes, France
-
Service de Chirurgie Digestive, CHU Estaing - CHRU Clermont Ferrand
Clermont-Ferrand, France
-
Service de Chirurgie Digestive, CHU de Besançon
Besançon, France
-
Service de Chirurgie Digestive, CHU de la Timone - Marseille
Marseille, France
-
Service de Chirurgie Digestive, Centre Georges François Leclerc - Dijon
Dijon, France
-
Service de Chirurgie Digestive, Centre Léon Bérard - Lyon
Lyon, France
-
Service de Chirurgie Digestive, Centre Oscar Lambret - Lille
Lille, France
-
Service de Chirurgie Digestive, Hôpital Albert Michallon - CHU de Grenoble
La Tronche, France
-
Service de Chirurgie Digestive, Hôpital Beaujon - APHP
Clichy, France
-
Service de Chirurgie Digestive, Hôpital Charles Nicolle - CHU de Rouen
Rouen, France
-
Service de Chirurgie Digestive, Hôpital Haut-Lévêque - CHU de Bordeaux
Bordeaux, France
-
Service de Chirurgie Digestive, Hôpital Lyon Sud - CHU Lyon
Lyon, France
-
Service de Chirurgie Digestive, Hôpital Pontchaillou - CHU Rennes
Rennes, France
-
Service de Chirurgie Digestive, Hôpital Purpan - CHU de Toulouse
Toulouse, France
-
Service de Chirurgie Digestive, Hôpital Saint-Antoine - APHP
Paris, France
-
Service de Chirurgie Digestive, Hôpital Saint-Louis - APHP Paris
Paris, France
-
Service de Chirurgie Digestive, Hôpital les Diaconnesses
Paris, France
-
Service de Chirurgie Digestive, Hôtel Dieu - CHU de Nantes
Nantes, France
-
Service de Chirurgie Digestive, Institut Bergonié
Bordeaux, France
-
Service de Chirurgie Digestive, Institut Paoli Calmette - Marseille
Marseille, France
-
Service de Chirurgie Digestive, Institut du Cancer de Montpellier
Montpellier, France
-
Service de Chirurgie Digestive,Institut de Cancérologie de Lorraine
Nancy, France
-
Service de Chirurgie Digestives, Hôpital Européen de Marseille
Marseille, France
-
Service de chirurgie digestive, CHRU de Nancy -Hôpital de Brabois
Vandœuvre-lès-Nancy, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Folfirinox chemotherapy (oxaliplatin, irinotecan, folinic acid, 5FU) and capecitabine
What this could lead to
If it works, this could allow more people with rectal cancer to keep their rectum and avoid a permanent stoma, improving quality of life.
What could go wrong
This is a completed phase 3 trial, but results may not apply to all patients. Adding chemotherapy also increases side effects like nerve damage and digestive issues.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.